Person:
YILDIZ, PELİN

Profile Picture
Status
Kurumdan Ayrılmıştır
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
PELİN
Last Name
YILDIZ
Name
Email Address
Birth Date

Filters

2014 - 20182
Reset filters

Settings

Has files: true × Author: GÜCİN, ZÜHAL × Author: ARICI, DILEK SEMA ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    Glomus tumor of the stomach
    (2018-03-01) YILDIZ, PELİN; GÜCİN, ZÜHAL; ARICI, DİLEK SEMA; MALYA, FATMA ÜMİT; Baysal, Birol; YILDIZ, PELİN; GÜCİN, ZÜHAL; ARICI, DILEK SEMA; MALYA, FATMA ÜMİT
    Glomus tumor is a rare benign mesenchymal neoplasm derived from the glomus body, an arteriovenous shunt mainly located in dermis and subcutis. The most common localization of this tumor is extremities, especially nailbed. Glomus tumor in the gastrointestinal system is a rare condition. Here we report a gastric glomus tumor to raise awareness of this tumor and show the difficulties in the diagnosis.
  • Thumbnail Image
    PublicationOpen Access
    Immunoexpression of TTF-1 in Non-Lung Tumors
    (2014-12-01T00:00:00Z) TOSUNER, ZEYNEP; ARICI, Dilek Sema; GÜCİN, ZÜHAL; BÜYÜKPINARBAŞILI, NUR; SÖNMEZ, FATMA CAVİDE; YILDIZ, PELİN; TOSUNER, ZEYNEP; ARICI, DILEK SEMA; GÜCİN, ZÜHAL; BÜYÜKPINARBAŞILI, NUR; SÖNMEZ, FATMA CAVİDE; YILDIZ, PELİN
    Objective: Thyroid transcription factor-1 (TTF-1) immunoexpression is frequently determined in small-cell lung carcinomas, as well as primary lung adenocarcinomas. While dealing with metastatic carcinomas, TTF-1 immunoexpression is a significant indicator of primary lung carcinomas. Recent studies have revealed that TTF-1 immunoexpression is also defined in non-lung cancers, such as squamous cell carcinomas of different sites and certain neuroendocrine tumors. The verified data obtained from these studies indicate that a straightforward diagnosis of primary lung carcinoma in cases with positive TTF-1 immunoexpression can cause diagnostic contradictions. The aim of our study is to investigate the immunoexpression status of TTF-1 in common non-lung tumors. Methods: A total of 85 cases that were diagnosed in our institute between the years 2011-2012 were included in our study. After a review of the pathological slides prepared from these tumors [colon adenocarcinoma (n: 15), renal cell carcinoma (n: 15), prostate adenocarcinoma (n: 15), invasive papillary urothelial carcinoma (n: 15), invasive ductal carcinoma of breast (n: 15), and neuroendocrine tumors (n: 10)] TTF-1 immunohistochemistry was applied. Semiquantative evaluation based on the distribution and intensity of the staining was performed by two pathologists, respectively. Results: Positive immunostaining was evident in only 1 case of colon adenocarcinoma out of 85 cases. Conclusion: Our study demonstrated that TTF-1 immunoexpression is a very rare finding (1%) in non-lung tumors. This result provides that anti-TTF-1 is a reliable antibody in the interpretation of primary lung carcinomas. In fact, further studies with a large number of cases are needed to confirm the sensitivity and specificity of TTF-1.